24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation

New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxacin or clofazimine, could improve treatment efficacy, safety, and tolerability, and free up resources within the health system. Following a change to WHO...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet global health Jg. 13; H. 2; S. e355 - e363
Hauptverfasser:	Sweeney, Sedona, Laurence, Yoko V, Berry, Catherine, Singh, Maninder Pal, Dodd, Matthew, Fielding, Katherine, Kazounis, Emil, Moodliar, Ronelle, Solodovnikova, Varvara, Tigay, Zinaida, Liverko, Irina, Parpieva, Nargiza, Butabekov, Ilhomjon, Usmanova, Ruzilya, Rassool, Mohammed, Motta, Ilaria, Nyangweso, George Mokua, Jolivet, Pascal, Abdrasuliev, Tleubergen, Moe, Soe, Aw, Pei Sun, Samieva, Nazgul, Nyang'wa, Bern-Thomas
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Elsevier Ltd 01.02.2025
Schlagworte:	Administration, Oral Adult Antitubercular Agents - administration & dosage Antitubercular Agents - economics Antitubercular Agents - therapeutic use Cost-Benefit Analysis Diarylquinolines - economics Diarylquinolines - therapeutic use Drug Therapy, Combination Female Humans Male Quality-Adjusted Life Years Rifampin - therapeutic use South Africa Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - economics Tuberculosis, Pulmonary - drug therapy South Africa
ISSN:	2214-109X, 2214-109X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!